Plethora Solutions

Shareholder Information

Share Capital and Major Shareholders

As at 10 February 2016, the Company's share capital consisted of 823,297,685 ordinary shares of 1p each and on the assumption that all loan notes and warrants issued by the Company were converted in full, the Company's fully diluted share capital would be 1,082,368,616 ordinary shares of 1p each. This calculation is based on the assumption that certain warrant holders which have the option to subscribe for shares at a price of 15p per share will exercise these rights. If these options we not to be exercised, the fully diluted share capital will be 981,087,175 ordinary shares. Shareholders holding more than 3% of the issued share capital of Plethora Solutions Holdings PLC were:

Name of shareholderNumber of shares heldPercentage of issued share capital
MR JIM MELLON155,358,77118.87%
REGENT PACIFIC GROUP LIMITED86,799,49010.54%
MAVEN CAPITAL PARTNERS UK LLP52,356,5166.36%
BAKER BROTHERS ADVISORS49,581,3856.02%
HARGREAVES LANSDOWN ASSET MGT47,173,5955.73%
CORPORATE STAKEHOLDERS (UK)42,2000,0695.13%
WALKER CRIPS GROUP34,413,2054.18%
BARCLAYS BANK34,286,9474.16%
TD BANK FINANCIAL GROUP34,067,0704.17%
LLOYDS BANKING GROUP28,129,7116.42%
PRIVATE STAKEHOLDERS (UK)25,571,0273.11%

Director Shareholdings (other than major shareholders)

As at 10 February 2016, the shareholdings of the Directors of Plethora Solutions Holdings PLC were as follows:

Director Number of shares held Percentage of issued share capital
J Mellon* 242,158,261 29.41%
M Wyllie 1,759,127 0.26%
G Bailey 555,600 0.08%


Notes:

* - the holdings of Jim Mellon include those directly beneficially owned by him together with those held by investment funds in which he has an indirect beneficial interest;

Shares Not in Public Hands

Pursuant to the AIM Rules published in February 2010, and insofar as the Company is aware, as at 10 February 2016, 29.69% of the Company's AIM securities was not in public hands.

Restrictions on Transfer of AIM Securities

Pursuant to the AIM Rules published in February 2010, there are no restrictions on the transfer of the Company's AIM securities. The Company shares are not listed on any other exchanges or trading platforms.


This Product is a proprietary development stage pharmaceutical although the European MAA has been authorized by the European Commission. Information contained on this website is provided for business development and investor relations purposes only. Patients who suffer or believe they suffer from PE should contact their physician in the first instance.